Rhythm Pharmaceuticals Names Hunter Smith Interim CEO

Rhythm Pharmaceutical says the company’s Chief Financial Officer, has been named to the additional role of Interim Chief Executive Officer, effective immediately.

• Company says it has completed its rolling submission of an NDA to the FDA for setmelanotide for the treatment of pro-opiomelanocortin deficiency obesity and leptin receptor deficiency obesity
  • Rhythm has requested priority review for the application which, if granted, could provide a target FDA review period of six months from the application filing date
  • Company continues to anticipate that it will submit a Marketing Authorization Application to the European Medicines Agency in the second quarter of 2020
  • Says ...